1Department of Hemato-Oncology, Chonnam National University Medical School, Gwangju, Korea.
2Department of Otorhinolaryngology-Head and Neck Surgery, Chonnam National University Medical School, Gwangju, Korea.
3Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.
Copyright © 2007 Korean Cancer Association
Patient characteristics
Dose intensities of TPF* chemotherapy
*docetaxel, cisplatin, 5-FU.
Overall response to induction chemotherapy and chemoradiation therapy
*complete response; †partial response; ‡stable disease; §progressive disease; ∥chemoradiotherapy; ¶lymph node; **overall response rate.
Toxicity of TPF chemotherapy (n=135)
Hematological toxicity of TPF chemotherapy between the group of patients under 65 years and over 65 years of age (n=135)
*docetaxel, cisplatin, 5-FU.
*complete response; †partial response; ‡stable disease; §progressive disease; ∥chemoradiotherapy; ¶lymph node; **overall response rate.